Natixis Sells 14,205 Shares of Masimo Co. (NASDAQ:MASI)

Natixis lessened its holdings in Masimo Co. (NASDAQ:MASI - Free Report) by 98.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 181 shares of the medical equipment provider's stock after selling 14,205 shares during the quarter. Natixis' holdings in Masimo were worth $30,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. MetLife Investment Management LLC raised its stake in shares of Masimo by 9.3% during the fourth quarter. MetLife Investment Management LLC now owns 26,026 shares of the medical equipment provider's stock valued at $4,302,000 after acquiring an additional 2,214 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Masimo in the fourth quarter valued at $163,000. Capital Research Global Investors raised its position in Masimo by 80.5% during the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock worth $405,807,000 after purchasing an additional 1,094,647 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Masimo by 8.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 647,720 shares of the medical equipment provider's stock worth $107,076,000 after buying an additional 50,022 shares during the period. Finally, First Trust Advisors LP grew its position in shares of Masimo by 780.4% in the 4th quarter. First Trust Advisors LP now owns 47,328 shares of the medical equipment provider's stock valued at $7,823,000 after buying an additional 41,952 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. Wells Fargo & Company boosted their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Finally, Piper Sandler boosted their target price on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Masimo presently has an average rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Price Performance

Masimo stock opened at $163.74 on Friday. The stock's 50 day moving average price is $165.71 and its two-hundred day moving average price is $165.42. The stock has a market capitalization of $8.85 billion, a price-to-earnings ratio of 112.92 and a beta of 1.28. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. On average, equities analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.